GlassScriptPhysician profile
Paul M Karpecki
NPI 1619910569
$3,564,402.60
in general payments reported to CMS, 2019-2025
64 companies · $594K in 2025
The $594K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $544K · 2020: $474K · 2021: $529K · 2022: $445K · 2023: $459K · 2024: $520K · 2025: $594K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $786K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $417K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $182K · Honoraria: $92K · Travel and Lodging: $72K · Food and Beverage: $23K · Education: $97.99 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $786,311.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $417,492.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $182,140.00 |
| Honoraria | $91,500.00 |
| Travel and Lodging | $72,347.78 |
| Food and Beverage | $22,703.50 |
| Education | $97.99 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $602,690.40 | 2020-2025 | Acthar |
| Oasis Medical, INC. | $320,643.67 | 2019-2025 | Oasis Tears |
| Bausch & Lomb Americas INC. | $290,355.65 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $190,472.95 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171,442.05 | 2019-2021 | |
| Harrow Eye, LLC | $161,575.64 | 2023-2025 | Vevye, Iheezo, Triesence |
| Sun Pharmaceutical Industries INC. | $139,537.52 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Atlas Ocular, INC | $136,833.33 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $128,629.12 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $121,833.46 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Dompe US, INC. | $113,162.38 | 2019-2025 | Oxervate |
| Oculus, INC. | $110,000.00 | 2019-2025 | Keratograph, Keratograph 5m |
| Rxsight INC | $105,349.82 | 2020-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Ivantis, INC | $87,297.11 | 2019-2021 | |
| Maculogix, INC. | $76,276.85 | 2019-2021 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $67,416.03 | 2019 | |
| Sight Sciences, INC. | $66,870.74 | 2019-2025 | Tearcare System |
| Akorn, INC. | $51,693.25 | 2019-2020 | |
| Konan Medical USA, INC. | $50,750.00 | 2019-2020 | |
| Tearlab Corp | $48,591.17 | 2019-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Reichert, INC. | $46,000.00 | 2019-2023 | |
| Alcon Research LLC | $42,709.55 | 2019-2025 | Tryptyr |
| Allergan, INC. | $39,869.94 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $36,500.72 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $35,851.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $35,777.34 | 2019-2023 | Xiidra |
| Topcon Healthcare, INC. | $35,719.03 | 2019-2025 | |
| Haag-Streit USA, INC. | $35,000.00 | 2020-2021 | |
| Nordic Pharma, INC. | $27,480.56 | 2024-2025 | Lacrifill, Lacrifill |
| Mallinckrodt Enterprises LLC | $26,519.91 | 2019 | |
| Akorn Operating Company LLC | $25,000.00 | 2021 | |
| Abbvie INC. | $22,852.43 | 2022-2025 | |
| Oyster Point Pharma, INC. | $20,673.50 | 2022-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $15,847.47 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $14,250.00 | 2020 | |
| Lombart Brothers, INC. | $11,500.00 | 2022 | |
| Aerie Pharmaceuticals, INC. | $9,877.98 | 2019-2021 | |
| Dgh Technology, INC. | $9,750.00 | 2019 | |
| Horizon Therapeutics Plc | $6,063.73 | 2020-2023 | Tepezza |
| Astellas Pharma US INC | $5,074.46 | 2023 | |
| Eyepoint US, INC. | $4,250.00 | 2019-2020 | |
| Thea Pharma INC. | $4,073.24 | 2022-2024 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $2,875.00 | 2021-2024 | Cirrus Hd-Oct, Visumax, Clarus |
| Apellis Pharmaceuticals, INC. | $2,838.00 | 2023-2024 | Syfovre |
| Glaukos Corporation | $1,584.66 | 2019-2025 | Istent Infinite, Idosetr |
| Santen INC. | $1,350.00 | 2023 | Verkazia |
| Lkc Technologies, INC. | $1,250.00 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $630.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $383.33 | 2025 | |
| Coopervision INC. | $316.68 | 2019 | |
| Ani Pharmaceuticals, INC. | $274.96 | 2022-2025 | Purified Cortrophin Gel |
| Topcon Corporation | $238.37 | 2024 | |
| Ocular Therapeutix, INC. | $231.30 | 2021-2024 | Dextenza |
| Lensar, INC. | $141.34 | 2021 | |
| Amgen INC. | $71.58 | 2024-2025 | Tepezza |
| Optovue, INC. | $52.46 | 2021 | |
| Optos, INC. | $50.00 | 2019 | |
| Osmotica Pharmaceutical Corp. | $22.08 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Quidel Corporation | $11.07 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,043.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$306,711.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Karpecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.